> CPDR News
CHI Podium Presentation in Boston
Albert Dobi, Ph.D. will present a novel computational formula for the prediction of androgen receptor binding sites
October 4, 2005
On October 17, Albert Dobi, Ph.D. will present a novel computational formula for the prediction of androgen receptor binding sites. The finding is the result of an excellent international collaborative effort between the Center for Prostate Disease Research, Department of Surgery, Uniformed Services University and the Genomatix Software GmbH, Munich, Germany. www.genomatix.de
The focus of this research is on the androgen hormone signaling that is the main therapeutic target in prostate cancer. The objective of the collaboration is to identify genomic targets for androgen receptor that is important for the development of better prognostic, diagnostic and therapeutic tools. The findings will be published in the Journal of Molecular Biology, October 21 issue.
For further details please, visit the CPDR Gene Expression Database or view the PDF files below.
List of Human Promoters with ARE
GO List Biol Process ARE
GO List Molecular Function ARE
The CPDR mission is fulfilled primarily through its three principal programs – the Clinical Research Center, the Basic Science Research Program and the National Multicenter Prostate Cancer Database– and through a robust education and training program that operates out of its Headquarters location, the Clinical Research Center, and the original laboratories at USUHS. CPDR is also committed to patient outreach, primarily through its affiliation with the WRAMC US TOO! organization and through a heavy schedule of health fairs in which it participates.
